80 related articles for article (PubMed ID: 3227403)
1. Inhibition of tolbutamide metabolism by antimalarial drugs.
Karbwang J; Back DJ; Bunnag D; Breckenridge AM
Southeast Asian J Trop Med Public Health; 1988 Jun; 19(2):235-41. PubMed ID: 3227403
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro.
Riviere JH; Back DJ
Chem Biol Interact; 1986 Oct; 59(3):301-8. PubMed ID: 3769058
[TBL] [Abstract][Full Text] [Related]
3. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.
Baune B; Furlan V; Taburet AM; Farinotti R
Drug Metab Dispos; 1999 May; 27(5):565-8. PubMed ID: 10220483
[TBL] [Abstract][Full Text] [Related]
4. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.
Knodell RG; Hall SD; Wilkinson GR; Guengerich FP
J Pharmacol Exp Ther; 1987 Jun; 241(3):1112-9. PubMed ID: 3598900
[TBL] [Abstract][Full Text] [Related]
5. Polysaccharide peptides from COV-1 strain of Coriolus versicolor inhibit tolbutamide 4-hydroxylation in the rat in vitro and in vivo.
Yeung JH; Chan SL; Or PM
Food Chem Toxicol; 2006 Aug; 44(8):1414-23. PubMed ID: 16698161
[TBL] [Abstract][Full Text] [Related]
6. Effect of mefloquine on hepatic drug metabolism in the rat: comparative study with primaquine.
Riviere JH; Back DJ
Biochem Pharmacol; 1985 Feb; 34(4):567-71. PubMed ID: 3871613
[TBL] [Abstract][Full Text] [Related]
7. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.
Relling MV; Aoyama T; Gonzalez FJ; Meyer UA
J Pharmacol Exp Ther; 1990 Jan; 252(1):442-7. PubMed ID: 2299601
[TBL] [Abstract][Full Text] [Related]
8. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
Marathe PH; Shen DD; Nelson WL
Drug Metab Dispos; 1994; 22(2):237-47. PubMed ID: 8013280
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
Palamanda J; Feng WW; Lin CC; Nomeir AA
Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
[TBL] [Abstract][Full Text] [Related]
10. Gliclazide hydroxylation by rat liver microsomes.
Rieutord A; Stupans I; Shenfield GM; Gross AS
Xenobiotica; 1995 Dec; 25(12):1345-54. PubMed ID: 8719909
[TBL] [Abstract][Full Text] [Related]
11. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.
Purba HS; Back DJ; Orme ML
Br J Clin Pharmacol; 1987 Aug; 24(2):230-4. PubMed ID: 3620298
[TBL] [Abstract][Full Text] [Related]
12. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1.
Gallagher EP; Wienkers LC; Stapleton PL; Kunze KL; Eaton DL
Cancer Res; 1994 Jan; 54(1):101-8. PubMed ID: 8261428
[TBL] [Abstract][Full Text] [Related]
13. Determination of tolbutamide hydroxylation in rat liver microsomes by high-performance liquid chromatography: effect of psychoactive drugs on in vitro activity.
Ho JW; Moody DE
Life Sci; 1993; 52(1):21-8. PubMed ID: 8417276
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.
Back DJ; Tjia JF; Karbwang J; Colbert J
Br J Clin Pharmacol; 1988 Jul; 26(1):23-9. PubMed ID: 3203057
[TBL] [Abstract][Full Text] [Related]
15. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.
Miners JO; Smith KJ; Robson RA; McManus ME; Veronese ME; Birkett DJ
Biochem Pharmacol; 1988 Mar; 37(6):1137-44. PubMed ID: 3355588
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Ko JW; Sukhova N; Thacker D; Chen P; Flockhart DA
Drug Metab Dispos; 1997 Jul; 25(7):853-62. PubMed ID: 9224780
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
18. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
19. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro.
Murray M; Butler AM; Stupans I
J Pharmacol Exp Ther; 1994 Aug; 270(2):645-9. PubMed ID: 8071856
[TBL] [Abstract][Full Text] [Related]
20. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.
Doecke CJ; Veronese ME; Pond SM; Miners JO; Birkett DJ; Sansom LN; McManus ME
Br J Clin Pharmacol; 1991 Feb; 31(2):125-30. PubMed ID: 2049228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
